296 Children Had Hepatitis of Unknown Etiology by June 15, 2022
Overall, 89.9 percent of patients under investigation were hospitalized, 6.1 percent required a transplant, and 3.7 percent died
Life Expectancy in the U.S. Varies by Race, Ethnicity, State
Disparity in life expectancy across states greater when race/ethnicity are considered
More Than 18 Million Cancer Survivors Living in U.S. as of Jan. 1, 2022
Considerable racial disparities seen in treatment, with surgery receipt lower for Black versus White patients with NSCLC
Both Bariatric Surgery Methods Yield Similar 10-Year Results
No significant differences seen for remission of type 2 diabetes, dyslipidemia, obstructive sleep apnea, or prevalence of Barrett esophagus
Alarming Increase Seen in U.S. Deaths From Alcoholic Cirrhosis
Mortality rate increased more than threefold between 1999 and 2019
Sex Differences Seen in COVID-19 Sequelae, Long COVID
Following SARS-CoV-2 infection, women more likely to develop long COVID-19 syndrome than men
COVID-19 Tied to Progression of Chronic Liver Disease
About one in five patients with preexisting chronic liver disease develop progressive cholestasis after severe COVID-19
Risk for Existing, Incident T2D High in Children With NAFLD
Risk factors for incident T2D include female gender, BMI z-score, and more severe liver histology, including steatosis grade, fibrosis stage
Progress Seen in Proportion of Pregnant Persons With Hep C Screening
Percentage undergoing HCV screening test increased from 16.6 percent in quarter 1 of 2011 to 40.6 percent in quarter 2 of 2021
FDA Approves Skyrizi for Moderately to Severely Active Crohn Disease
Skyrizi is first specific interleukin-23 approved to treat Crohn disease
